Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27 (PLATO-dose)

This study has been completed.

Sponsor:

Collaborator:

University Hospital Fattouma Bourguiba

Information provided by (Responsible Party):

Les Laboratoires des Médicaments Stériles

ClinicalTrials.gov Identifier:

NCT01509365

First received: January 9, 2012

Last updated: May 6, 2015

Last verified: October 2014

History of Changes

Purpose

The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to 75 mg clopidogrel in the patient population overweight or obese with a body mass index (BMI) ≥ 27 kg.m-2.

Condition	Intervention	Phase
Cardiovascular Disease Overweight	Drug: clopidogrel	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Evaluation the Effect of the Double Maintenance Dose of Clopidogrel Versus Single Dose in Patients With Coronary Artery Disease With a BMI ≥ 27 kg.m-2

Resource links provided by NLM:

Drug Information available for: Clopidogrel bisulfate

U.S. FDA Resources

Further study details as provided by Les Laboratoires des Médicaments Stériles:

Primary Outcome Measures:

Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation [ Time Frame: 6 months ]

Secondary Outcome Measures:

ADP-induced platelet aggregation assessed by VerifyNow test [ Time Frame: 7 days after selection of patients ]


Enrollment:	116
Study Start Date:	December 2011
Study Completion Date:	May 2015
Primary Completion Date:	February 2015 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
No Intervention: sensible Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.
Active Comparator: simple dose Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.	Drug: clopidogrel 1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
Experimental: double dose Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.	Drug: clopidogrel 2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.

Detailed Description:

The goal is to evaluate the effect of the double maintenance dose of clopidogrel versus single dose in patients with proven coronary and with BMI ≥ 27 kg.m-2 1 - Biologically: study and compare the respective effects of the double dose and single dose of clopidogrel on platelet aggregation.

2 - Clinically: to study and compare the cardiovascular events and adverse effects depending on the dose of clopidogrel.

Eligibility


Ages Eligible for Study:	20 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female,
Old (e) of more than 20 years
BMI ≥ 27kg.m-2
Patients hospitalized for acute coronary syndrome (Whatever the ST segment and troponin dosage)
Patients with proven coronary candidates for treatment with Clopidogrel (who received a loading dose of 600mg over 2 hours or treated with 75 mg/day or 150mg / day of clopidogrel for longer than 7 days)

Exclusion Criteria:

Patients unwilling.
Patient participating in another study.
Patients with cardiogenic shock
Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability
Patients scheduled for surgery in less than 6 months
ischemic stroke older than 6 weeks.
History of hemorrhagic stroke (any time)
Patients on or candidates for AVK
Patients with a different anti ADP (ticlopidine, prasugrel)
Patients with an indication against clopidogrel (side effects, bleeding ...)
Thrombocytopenia < 100000/mm3
anemia (Ht < 30%)
Thrombocythaemia (Ht > 52%)
Pregnancy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01509365

Locations


Tunisia
cardiology department, hospital Fattouma Bourguiba
Monastir, Tunisia, 5000

Sponsors and Collaborators

Les Laboratoires des Médicaments Stériles

University Hospital Fattouma Bourguiba

Investigators


Study Chair:	Faouzi Maatouk, MD	hospital Fattouma Bourguiba
Principal Investigator:	Khaldoun Ben Hamda, MD	Hospital Fattouma Bourguiba
Principal Investigator:	Sonia Hamdi, MD	Hospital Fattouma Bourguiba
Principal Investigator:	Mohsen Hassine	Hospital Fattouma Bourguiba

More Information


Responsible Party:	Les Laboratoires des Médicaments Stériles
ClinicalTrials.gov Identifier:	NCT01509365 History of Changes
Other Study ID Numbers:	03 PID 11
Study First Received:	January 9, 2012
Last Updated:	May 6, 2015

Keywords provided by Les Laboratoires des Médicaments Stériles:


cardiovascular disease maintenance dose clopidogrel overweight antiplatelet agents

Additional relevant MeSH terms:


Cardiovascular Diseases Overweight Body Weight Signs and Symptoms Clopidogrel Ticlopidine Platelet Aggregation Inhibitors Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists	Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Fibrinolytic Agents Fibrin Modulating Agents Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors

ClinicalTrials.gov processed this record on June 26, 2017

To Top